Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enalapril/lercanidipine - Recordati

Drug Profile

Enalapril/lercanidipine - Recordati

Alternative Names: Atover; Carmen ACE; Coripren; Lercaprel; Lercapress; Zan-Extra; Zaneril; Zanextra; Zanipress; Zanipril; Zanitek

Latest Information Update: 06 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Recordati
  • Class Antihypertensives; Dihydropyridines; Dipeptides; Small molecules
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension
  • Registered Essential hypertension

Most Recent Events

  • 06 Feb 2019 Chemical structure information added
  • 25 Jan 2019 NDR batch 14: no updates
  • 05 Aug 2016 Meda has been acquired by Mylan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top